Sydney Stewart, Author at BioTuesdays

Executive Moves

Canopy Growth names Mike Lee as acting CFO

Canopy Growth (TSX:WEED; NYSE:CGC) appointed Mike Lee as acting CFO, effective June 1, and subject to Health Canada security clearance required for all officers and directors of the company.

May 21, 2019

Executive Moves

Zenabis provides operational update; appoints Natascha Kiernan to board

Zenabis Global (TSXV:ZENA) provide an update on its recent cannabis production figures, anticipated future harvests, facility construction and licensing status, and medical program update.

May 21, 2019

Developments

Mustang Bio gets FDA orphan drug designation for malignant glioma

Mustang Bio (NASDAQ:MBIO) and development partner, Nationwide Children’s Hospital (NCH), received FDA orphan drug designation for MB-108 for the treatment of malignant glioma. Malignant glioma is a type of brain cancer...

May 17, 2019

Developments

FDA accepts Cue Biopharma IND for HPV-associated cancer candidate

Cue Biopharma’s (NASDAQ:CUE) IND for CUE-101, an immuno-oncology candidate for human papilloma virus (HPV)-associated cancers, had been accepted by the FDA. The majority of HPV-associated cancers are caused by the HPV16...

May 16, 2019

Executive Moves

Neptune Wellness names Martin Landry as chief of corporate development and strategy

Neptune Wellness Solutions (NASDAQ:NEPT; TSX:NEPT) appointed Martin Landry to the new position of chief of corporate development and strategy, effective May 27.

May 14, 2019

Developments

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

uniQure (NASDAQ:QURE) reported new data from its Phase 2b trial of hemophilia B candidate, AMT-061, which demonstrated sustained activity six months after administration in three patients. AMT-061 is a therapy that...

May 10, 2019

Developments

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

The FDA has accepted Esperion’s (NASDAQ:ESPR) NDAs for its bempedoic acid and bempedoic acid-ezetimibe combination tablets for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and...

May 9, 2019

Executive Moves

IntelGenx names André Godin to additional post of president

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) appointed André Godin to the additional position of president. He continues as CFO and will continue to report to CEO, Dr. Horst Zerbe.

May 9, 2019

Developments

Canopy Growth unveils new cannabis commercial medical and research unit, Spectrum Therapeutics

Canopy Growth (TSX:WEED; NYSE:CGC) unveiled Spectrum Therapeutics, a new global brand that will encompass all of the company’s ongoing commercial medical and clinical research operations. These include Spectrum...

May 7, 2019

Developments

Savara gets FDA fast track designation for autoimmune lung disease

The FDA granted Savara’s (NASDAQ:SVRA) Molgradex fast track designation for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). aPAP occurs when the body’s immune system attacks granulocyte-macrophage...

May 6, 2019

Author - Sydney Stewart

Canopy Growth names Mike Lee as acting CFO

Zenabis provides operational update; appoints Natascha Kiernan to board

Mustang Bio gets FDA orphan drug designation for malignant glioma

FDA accepts Cue Biopharma IND for HPV-associated cancer candidate

Neptune Wellness names Martin Landry as chief of corporate development and strategy

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

IntelGenx names André Godin to additional post of president

Canopy Growth unveils new cannabis commercial medical and research unit, Spectrum Therapeutics

Savara gets FDA fast track designation for autoimmune lung disease

Subscribe